Handelsbanken Fonder’s Madrigal Pharmaceuticals MDGL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.05M Buy
5,680
+320
+6% +$164K 0.01% 658
2026
Q1
$2.81M Buy
5,360
+280
+6% +$134K 0.01% 626
2025
Q4
$2.96M Buy
5,080
+680
+15% +$347K 0.01% 617
2025
Q3
$2.02M Hold
4,400
– – 0.01% 721
2025
Q2
$1.33M Sell
4,400
-400
-8% -$119K ﹤0.01% 833
2025
Q1
$1.59M Sell
4,800
-28,000
-85% -$9.2M 0.01% 742
2024
Q4
$10.1M Buy
32,800
+300
+0.9% +$84.4K 0.04% 357
2024
Q3
$6.9M Buy
32,500
+900
+3% +$230K 0.03% 396
2024
Q2
$8.85M Buy
31,600
+9,300
+42% +$2.21M 0.04% 356
2024
Q1
$5.96M Buy
22,300
+19,000
+576% +$4.48M 0.03% 423
2023
Q4
$764K Buy
3,300
+500
+18% +$87.5K ﹤0.01% 927
2023
Q3
$409K Hold
2,800
– – ﹤0.01% 1151
2023
Q2
$647K Sell
2,800
-1,000
-26% -$271K ﹤0.01% 943
2023
Q1
$921K Hold
3,800
– – 0.01% 726
2022
Q4
$1.1M Hold
3,800
– – 0.01% 624
2022
Q3
$247K Hold
3,800
– – ﹤0.01% 1351
2022
Q2
$272K Hold
3,800
– – ﹤0.01% 1376
2022
Q1
$373K Hold
3,800
– – ﹤0.01% 1393
2021
Q4
$322K Buy
3,800
+1,100
+41% +$90.4K ﹤0.01% 1593
2021
Q3
$215K Hold
2,700
– – ﹤0.01% 1646
2021
Q2
$263K Buy
2,700
+300
+13% +$35.5K ﹤0.01% 1661
2021
Q1
$281K Hold
2,400
– – ﹤0.01% 1465
2020
Q4
$267K Buy
+2,400
New +$293K ﹤0.01% 1452

Other funds holding MDGL

Handelsbanken Fonder's MDGL Position: Q2 2026 in Review

Handelsbanken Fonder increased its Madrigal Pharmaceuticals (MDGL) stake by 6% in Q2 2026, buying an estimated $164K and bringing the position to 5,680 shares worth $3.05M. The position accounts for 0.01% of the portfolio, ranked #658.

Handelsbanken Fonder first reported a position in MDGL in Q4 2020 and has held it in 23 quarters since. The position peaked at $10.1M in Q4 2024. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Handelsbanken Fonder held 5,680 shares of Madrigal Pharmaceuticals worth $3.05M as of Q2 2026.
  • Handelsbanken Fonder bought 320 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $164K.
  • Madrigal Pharmaceuticals made up 0.01% of Handelsbanken Fonder's portfolio in Q2 2026, its #658 holding.
  • Handelsbanken Fonder first reported a position in Madrigal Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
  • Handelsbanken Fonder's Madrigal Pharmaceuticals position peaked at $10.1M in Q4 2024.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Handelsbanken Fonder's 13F filing for Q2 2026, filed 10 Jul 2026.